AbbVie Inc (ABBV)vsOpus Genetics, Inc. (IRD)
ABBV
AbbVie Inc
$251.07
-0.23%
HEALTHCARE · Cap: $447.62B
IRD
Opus Genetics, Inc.
$4.18
+5.26%
HEALTHCARE · Cap: $336.04M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 524134% more annual revenue ($62.82B vs $11.98M). ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
IRD
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$251.07
$104.85 premium
Margin of Safety
+45.1%
Fair Value
$5.99
Current Price
$4.18
$1.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
IRD carries more volatility with a beta of 0.55 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 19/100) and 12.4% revenue growth. IRD offers better value entry with a 45.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases impacting vision. By leveraging advanced gene-editing technologies and a robust research foundation, Opus aims to fulfill critical unmet medical needs in ocular health. With a promising pipeline supported by active clinical trials and strategic collaborations, the company is well-positioned to make significant contributions to patient care while presenting compelling growth opportunities for institutional investors in the dynamic healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?